Showing results (11-20 of 28) with videos related to
Sort By:
Pageof 3
Journal of Clinical Pharmacology|November 18, 2020
Chimeric Antigen Receptor T Cell Therapies: A Review of Cellular Kinetic-Pharmacodynamic Modeling ApproachesAnwesha Chaudhury, Xu Zhu, Lulu Chu, et al.Nature Communications|May 8, 2015
IκBβ enhances the generation of the low-affinity NFκB/RelA homodimerRachel Tsui, Jeffrey D Kearns, Candace Lynch, et al.Frontiers in Pharmacology|May 2, 2022
Navigating Between Right, Wrong, and Relevant: The Use of Mathematical Modeling in Preclinical Decision MakingAnna Kondic, Dean Bottino, John Harrold, et al.Molecular Systems Biology|May 9, 2007
A homeostatic model of IkappaB metabolism to control constitutive NF-kappaB activityEllen L O'Dea, Derren Barken, Raechel Q Peralta, et al.Genes & Development|August 5, 2008
Encoding NF-kappaB temporal control in response to TNF: distinct roles for the negative regulators IkappaBalpha and A20Shannon L Werner, Jeffrey D Kearns, Victoria Zadorozhnaya, et al.Journal of Pharmacokinetics and Pharmacodynamics|December 17, 2024
QSP modeling of a transiently inactivating antibody-drug conjugate highlights benefit of short antibody half lifeEshita Khera, Lekshmi Dharmarajan, Dominik Hainzl, et al.Cell|January 27, 2007
A fourth IkappaB protein within the NF-kappaB signaling moduleSoumen Basak, Hana Kim, Jeffrey D Kearns, et al.Nature Immunology|October 23, 2012
Control of RelB during dendritic cell activation integrates canonical and noncanonical NF-κB pathwaysVincent F-S Shih, Jeremy Davis-Turak, Monica Macal, et al.Investigational New Drugs|November 18, 2016
A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecanJames M Cleary, Autumn J McRee, Geoffrey I Shapiro, et al.Science Translational Medicine|February 5, 2016
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutationsSabrina Arena, Giulia Siravegna, Benedetta Mussolin, et al.Pageof 3